Asset Details
Do you wish to reserve the book?
A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects
Do you wish to request the book?
A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects
2012
Overview
Aim： To investigate the pharmacokinetics, pharmacodynamics, and safety of higenamine, an active ingredient of Aconite root, in healthy Chinese volunteers. Methods：Ten subjects received continuous, intravenous infusion of higenamine at gradually escalating doses from 0.5 to 4.0 pg.kg^1.min 1, each dose was given for 3 min. Blood and urine samples were collected at designated time points to measure the concentrations of higenamine. Pharmacodynamics was assessed by measuring the subject＇s heart rate. A nonlinear mixed-effect modeling approach, using the software Phoenix NLME, was used to model the plasma concentration-time profiles and heart rate. Results： Peak concentrations （Cmax） of higenamine ranged from 15.1 to 44.0 ng/mL. The half-life of higenamine was 0.133 h （range, 0.107-0.166 h）, while the area under concentration-time curve （AUC）, extrapolated to infinity, was 5.39 ng-h.mL1 （range, 3.2-6.8 ng.h.mLl）. The volume of distribution （V） was 48 L （range, 30.8-80.6 L）. The total clearance （CL） was 249 L/h （range, 199-336 L/h）. Within 8 h, 9.3% （range, 4.6%-12.4%） of higenamine was recovered in the urine. The pharmacokinetics of higenamine was successfully described using a two-compartment model with nonlinear clearance. In the pharmacodynamic model, heart rates were related to the plasma drug concentrations using a simple direct effect model with baseline. The Eo, Emax, and EC5o were 68 bpm, 73 bpm and 8.1 pg/L, respectively. Conclusion： Higenamine has desirable pharmacokinetic and pharmacodynamic characteristics. The results provide important informa tion for future clinical studies on higenamine.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Alkaloids - administration & dosage
/ Alkaloids - pharmacokinetics
/ Biomedical and Life Sciences
/ Cardiotonic Agents - administration & dosage
/ Cardiotonic Agents - pharmacokinetics
/ Cardiotonic Agents - pharmacology
/ China
/ Dose-Response Relationship, Drug
/ Female
/ Humans
/ Male
/ Original
/ Tetrahydroisoquinolines - administration & dosage
/ Tetrahydroisoquinolines - pharmacokinetics
/ Tetrahydroisoquinolines - pharmacology
/ Vaccine
/ 中国
/ 乌药
/ 健康
/ 影响模型
/ 浓度测量
/ 碱
/ 药代动力学
/ 药效学
